ReviewMolecular biology reports2026
RNA modifications as innovative pharmaceutical targets: emerging drug delivery strategies and precision therapeutics for cancer immunotherapy and metabolic diseases.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA modifications have emerged as an important regulatory layer that influences gene expression beyond conventional genetic and epigenetic mechanisms. Among the various epitranscriptomic modifications, N6-methyladenosine (m6A), 5-methylcytosine (m5C), and pseudouridine (Ψ) have been extensively investigated for their roles in RNA stability, splicing, translation, immune regulation, and metabolic homeostasis. Increasing evidence suggests that dysregulation of these modifications contributes to cancer progression, immune evasion, therapeutic resistance, and metabolic disorders, suggesting their potential as therapeutic targets. This review summarizes recent advances in endogenous epitranscriptomic RNA modifications and discusses their relevance in cancer immunotherapy and metabolic diseases. In addition, emerging therapeutic approaches targeting RNA-modifying enzymes, including writers, erasers, and readers, are discussed along with the development of antisense oligonucleotides, RNA-based therapeutics, and delivery systems. Recent progress in lipid nanoparticles, polymeric carriers, and targeted delivery platforms has improved the stability, specificity, and translational potential of RNA-targeted therapies. The review also highlights current challenges associated with clinical translation, including delivery efficiency, therapeutic specificity, and patient heterogeneity. Overall, epitranscriptomic RNA modifications may provide new opportunities for the development of precision therapeutic strategies for cancer and metabolic diseases.
Indexed as
Identifiers
42397569What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.